Long-term efficacy and safety of zoledronic acid compared with pamidronate in the treatment of myeloma bone disease

Acta Haematologica Polonica

Volumn 35, Issue 2, 2004, Pages 227-241

  Kraj, Maria ^a   Pogłód, Ryszard ^a   Maj, Stanisław ^a   Pawlikowski, Jan ^a   Sokołowska, Urszula ^a   Szczepanik, Janusz ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Bisphosphonates; Multiple myeloma; Osteolytic lesions; Pamidronate; Zoledronic acid

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PREDNISONE; VINCRISTINE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE REMODELING; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; HYPOTENSION; LIVER TOXICITY; MALE; MORTALITY; MULTIPLE MYELOMA; MYALGIA; MYELODYSPLASIA; NEPHROTOXICITY; OSTEOLYSIS; PATHOLOGIC FRACTURE; PHARYNX TUMOR; SPINAL CORD COMPRESSION; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 4644269743     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12: 220-229.
2. Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of interavenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001; 91: 144-154.
3. Berenson JR, Vescio R, Rosen L, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001; 7: 478-485.
4. Berenson JR, Rosen L, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200.
5. Centkowski P, Kraj M, Kruk B, Sokołowska U. Osteoprotegerin and sRANKL serum levels in multiple myeloma patients: Centr Eur J Immunol 2002; 27: 129-135.
6. Croucher P, Hijzen A, Shipman CM, et al. Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma. Blood 2001; 98: 160a.
7. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999; 93: 1697-1706.
8. Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999; 14: 2048-2056.
9. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9: 745-751.
10. Kraj M, Pogłód R, Pawlikowski J, Maj S. The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma. Acta Haemat Pol 2000; 31: 379-389.
11. Kraj M. New concepts in the pathogenesis of myeloma bone disease. Acta Haemal Pol 2003; 34 supl 1: 105-112.
12. Kraj M, Pogłód R, Maj S, et al. Safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients are comparable. 1. Hemat J 2003; 4 Suppl. 1: S198. 2. Acta Haemal Pol 2003; 34 supl. 2: 278.
13. Kraj M, Pogłód R, Maj S, et al. Safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients are comparable. 1. Hemat J 2003; 4 Suppl. 1: S198. 2. Acta Haemal Pol 2003; 34 supl. 2: 278.
14. Kraj M, Pogłód R, Mendek-Czajkowska E, Owczarska K. Reparacja szpiczakowych uszkodzeń osteolitycznych krȩgów w wyniku leczenia napromienianiem i pamidronianem lub kwasem zoledronowym. Acta Haemal Pol 2003; 34 supl. 2: 397.
15. Kauzmann V, Bauer E, Feurle J, et al. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-392.
16. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19: 558-567.
17. Pan B, Farrugia AN, To LB, Zannettino ACW. The nitrogen - containing bisphosphonate, zoledronic acid regulates RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). Hemat J 2003; 4 Suppl 1: S 158.
18. Pan B, To LB, Findlay M, et al. The nitrogen-containing bisphosphonate, zoledronic acid increases mineneralization of human bone-derived cells in vitro. Hemat J 2003; 4 Suppl 1: S156.
19. Rosen LS, Gordon D, Kamiński M, et al. Zoledronic add versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
20. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic add compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. A randomized, double blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
21. Shipman CM, Rogers MJ, Apperley JF, et al. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997; 98: 665-672.
22. Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistc induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000; 14: 841-844.
23. Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteclastogenesis and is dependent on osteodast activity. Br J Haematol 2002; 116: 278-290.